Advanced

Apo-lipoproteins, lipids and risk of cancer.

Borgquist, Signe LU ; Butt, Talha LU ; Almgren, Peter LU ; Shiffman, Dov; Stocks, Tanja LU ; Orho-Melander, Marju LU ; Manjer, Jonas LU and Melander, Olle LU (2016) In International Journal of Cancer 138(11). p.2648-2656
Abstract
The epidemiological evidence for an obesity-cancer association is solid, whereas the association between obesity-associated lipoprotein levels and cancer is less evident. We investigated circulating levels of Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) and association to risk of overall cancer and common cancer forms. The Malmö Diet and Cancer Study, a population-based prospective cohort study, enrolled 17,035 women and 11,063 men (1991-1996). Incident cancer cases were ascertained by record linkage with the Swedish Cancer Registry until end of follow-up, Jan 1(st) 2012. Baseline serum levels of ApoA1 and ApoB were analyzed for the entire cohort, and HDL-C and LDL-C levels in... (More)
The epidemiological evidence for an obesity-cancer association is solid, whereas the association between obesity-associated lipoprotein levels and cancer is less evident. We investigated circulating levels of Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) and association to risk of overall cancer and common cancer forms. The Malmö Diet and Cancer Study, a population-based prospective cohort study, enrolled 17,035 women and 11,063 men (1991-1996). Incident cancer cases were ascertained by record linkage with the Swedish Cancer Registry until end of follow-up, Jan 1(st) 2012. Baseline serum levels of ApoA1 and ApoB were analyzed for the entire cohort, and HDL-C and LDL-C levels in 5,281 participants. Hazard ratios, with 95% confidence interval, were calculated using Cox's proportional hazards analysis. In the entire cohort, none of the exposures were related to overall cancer risk (HRadj ApoA1=0.98, 95%CI: 0.95,1.01; HRadj ApoB=1.01, 95%CI: 0.98-1.04). Among men, ApoB was positively associated with cancer risk (HRadj ApoB=1.06, 95%CI: 1.01,1.10). Female breast cancer risk was inversely associated with ApoB (HRadj =0.92, 95%CI: 0.86,0.99). Among both genders, ApoA1 was inversely associated with lung cancer risk (HRadj =0.88, 95%CI: 0.80,0.97), whereas high ApoB increased lung cancer risk (HRadj =1.08, 95%CI: 0.99,1.18). Colorectal cancer risk was increased with high ApoB (HRadj =1.08, 95%CI: 1.01,1.16) among both genders. Apolipoprotein levels were not associated with prostate cancer incidence. Circulating levels of apolipoproteins are associated with overall cancer risk in men and across both genders with breast, lung, and colorectal cancer risk. Validation of these findings may facilitate future primary prevention strategies for cancer. This article is protected by copyright. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
138
issue
11
pages
2648 - 2656
publisher
John Wiley & Sons
external identifiers
  • pmid:26804063
  • scopus:84958817685
  • wos:000372913400011
ISSN
0020-7136
DOI
10.1002/ijc.30013
language
English
LU publication?
yes
id
4f3c33e2-55ab-4079-8336-2cbeb304fad9 (old id 8573904)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26804063?dopt=Abstract
date added to LUP
2016-02-04 09:28:52
date last changed
2017-08-07 11:11:59
@article{4f3c33e2-55ab-4079-8336-2cbeb304fad9,
  abstract     = {The epidemiological evidence for an obesity-cancer association is solid, whereas the association between obesity-associated lipoprotein levels and cancer is less evident. We investigated circulating levels of Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) and association to risk of overall cancer and common cancer forms. The Malmö Diet and Cancer Study, a population-based prospective cohort study, enrolled 17,035 women and 11,063 men (1991-1996). Incident cancer cases were ascertained by record linkage with the Swedish Cancer Registry until end of follow-up, Jan 1(st) 2012. Baseline serum levels of ApoA1 and ApoB were analyzed for the entire cohort, and HDL-C and LDL-C levels in 5,281 participants. Hazard ratios, with 95% confidence interval, were calculated using Cox's proportional hazards analysis. In the entire cohort, none of the exposures were related to overall cancer risk (HRadj ApoA1=0.98, 95%CI: 0.95,1.01; HRadj ApoB=1.01, 95%CI: 0.98-1.04). Among men, ApoB was positively associated with cancer risk (HRadj ApoB=1.06, 95%CI: 1.01,1.10). Female breast cancer risk was inversely associated with ApoB (HRadj =0.92, 95%CI: 0.86,0.99). Among both genders, ApoA1 was inversely associated with lung cancer risk (HRadj =0.88, 95%CI: 0.80,0.97), whereas high ApoB increased lung cancer risk (HRadj =1.08, 95%CI: 0.99,1.18). Colorectal cancer risk was increased with high ApoB (HRadj =1.08, 95%CI: 1.01,1.16) among both genders. Apolipoprotein levels were not associated with prostate cancer incidence. Circulating levels of apolipoproteins are associated with overall cancer risk in men and across both genders with breast, lung, and colorectal cancer risk. Validation of these findings may facilitate future primary prevention strategies for cancer. This article is protected by copyright. All rights reserved.},
  author       = {Borgquist, Signe and Butt, Talha and Almgren, Peter and Shiffman, Dov and Stocks, Tanja and Orho-Melander, Marju and Manjer, Jonas and Melander, Olle},
  issn         = {0020-7136},
  language     = {eng},
  month        = {01},
  number       = {11},
  pages        = {2648--2656},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Apo-lipoproteins, lipids and risk of cancer.},
  url          = {http://dx.doi.org/10.1002/ijc.30013},
  volume       = {138},
  year         = {2016},
}